01—Abstract
Summary
Summary of the 8-K filed February 27, 2024. Cited figures are marked; the original filing is the authoritative source.
On February 22, 2024, Boston Scientific (BSX) priced and, on February 27, 2024, completed a €2.0 billion senior notes offering issued by its wholly owned finance subsidiary, American Medical Systems Europe B.V.
The offering comprises €750 million of 3.375%a notes due 2029 and €1.25 billion of 3.500% notes due 2032, fully and unconditionally guaranteed by the parent. Net proceeds were approximately €1.980 billion. The proceeds, together with commercial paper borrowings and cash on hand, are earmarked primarily to finance the cash purchase price of the previously announced acquisition of Axonics, Inc. (agreed January 8, 2024), with any remaining proceeds used to repay the 3.450% senior notes maturing March 2024 and for general corporate purposes.
For investors, the key development is the scale of incremental debt tied to the Axonics deal, which will increase BSX's leverage until the acquisition closes and debt is serviced from operating cash flow. The notes carry a special mandatory redemption feature at 101%b of principal plus accrued interest if the Axonics acquisition is not consummated by the outside date (January 8, 2025, extendable to no later than January 8, 2026) or if the company notifies the trustee it will not pursue the deal. This provides a backstop protecting noteholders, and by extension limits the company's downside exposure if the transaction fails, though it also means a failed deal would require a near-term cash outlay to retire the notes.
The filing is largely a financing disclosure rather than a change in operating results. The Indenture's covenants restrict mergers or asset transfers of all or substantially all assets and limit liens, subject to customary exceptions. Investors should monitor the Axonics closing timeline, the company's commercial paper usage, and the leverage profile in upcoming quarterly reports.
02—Key points
Key Highlights
- AMS Europe B.V., a wholly owned BSX finance subsidiary, completed a €2.0 billion senior notes offering on February 27, 2024, guaranteed by Boston Scientific Corporation.
- Tranches: €750 million of 3.375% notes due 2029 and €1.25 billion of 3.500% notes due 2032; net proceeds approximately €1.980 billion.
- Proceeds, along with commercial paper and cash on hand, are primarily earmarked to fund the cash purchase price of the Axonics, Inc. acquisition agreed January 8, 2024.
- Excess proceeds may repay the 3.450% senior notes maturing March 2024, pay accrued interest on them, or fund general corporate purposes.
- Special mandatory redemption at 101% of principal plus accrued interest applies if the Axonics deal is not consummated by the outside date (January 8, 2025, extendable to January 8, 2026) or if BSX elects not to pursue it.
- Indenture covenants restrict mergers or transfers of substantially all assets and limit liens, subject to customary exceptions.
- Notes were issued under an existing shelf registration on Form S-3 (File No. 333-262937), with listing applied for on Euronext Dublin.
03—Questions
Frequently Asked Questions
What was BSX's February 2024 debt offering and how large was it?
Its finance subsidiary, American Medical Systems Europe B.V., sold €2.0 billion of senior notes in two tranches: €750 million of 3.375% notes due 2029 and €1.25 billion of 3.500% notes due 2032. Net proceeds were approximately €1.980 billion after underwriting discounts and expenses.
What is the money being used for?
The primary use is to finance the cash purchase price of the Axonics, Inc. acquisition, along with related fees and expenses. Any proceeds not used for that purpose may repay BSX's 3.450% senior notes maturing in March 2024, pay related accrued interest, or fund general corporate purposes.
What happens to the notes if the Axonics acquisition does not close?
AMS Europe must redeem each series of notes at 101% of principal plus accrued and unpaid interest. This is triggered if the deal is not completed by the later of January 8, 2025 (extendable to no later than January 8, 2026) or five business days after any agreed extension of the merger agreement's Outside Date, or if the company tells the trustee it will not pursue the acquisition.
Does this offering change Boston Scientific's overall credit obligations?
Yes, it adds roughly €2 billion of new debt, guaranteed by the parent, which increases total leverage until the Axonics deal closes and the debt is serviced from cash flow. The notes are issued under an indenture dated March 8, 2022, with covenants restricting certain mergers and liens, subject to important exceptions described in that indenture.
Will investors see any immediate impact on operating results from this filing?
The filing itself does not report new financial results or operating performance. Its effects on results will depend on the timing of the Axonics closing, interest expense on the new notes, and how the company funds the purchase price, which investors should track in upcoming quarterly reports.
04—Continue